- Home
- CMU vs AVTX Comparison
CMU vs AVTX Comparison
Compare CMU & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMU | AVTX |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CMU | AVTX |
|---|---|---|
| Price | $3.49 | $19.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.14 |
| AVG Volume (30 Days) | 82.4K | ★ 354.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.78 | $3.39 |
| 52 Week High | $3.38 | $20.56 |
Technical Indicators
Market Signals| Indicator | CMU | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 60.33 |
| Support Level | $3.46 | $15.53 |
| Resistance Level | $3.53 | $20.45 |
| Average True Range (ATR) | 0.02 | 1.45 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 28.57 | 76.69 |
Price Performance
Historical ComparisonAbout CMU MFS Municipal Income Trust
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).